Evidence map›Paper›PMID 15155420›Full record

Trial reportBritish journal of sports medicine2004

Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a).

F Hartgens, G Rietjens, H A Keizer, H Kuipers, B H R Wolffenbuttel

Open access · bronzeAbstract readClinical TrialRandomized Controlled Trial
In one paragraph

Trial report in British journal of sports medicine, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 2 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 207 citations in OpenAlex.

  1. Nandrolone Decanoate: Use, Abuse and Side Effects.Medicina (Kaunas, Lithuania) · 2020
    Pooled it
  2. Guideline
  3. Review
  4. Review
  5. Review
  6. Observational
  7. Review
  8. Association of vitamins, minerals, and lead with lipoprotein(a) in a cross-sectional cohort of US adults.International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition · 2023
    Article
  9. Anabolic androgenic steroids and cardiomyopathy: an update.Frontiers in cardiovascular medicine · 2023
    Review
  10. Management of Dyslipidemia in Endocrine Diseases.Endocrinology and metabolism clinics of North America · 2022
    Review
  11. Article
  12. Anabolic androgenic steroid-induced liver injury: An update.World journal of gastroenterology · 2022
    Review
  13. Review
  14. Review
  15. Dietary Supplements as Source of Unintentional Doping.BioMed research international · 2022
    Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

F HartgensNetherlands Centre for Doping Affairs, Capelle aan den IJssel, The Netherlands. fhartgens@home.nl
G Rietjens
H A Keizer
H Kuipers
B H R Wolffenbuttel
Maastricht University · NLIJsselland Ziekenhuis · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo investigate the effects of two different regimens of androgenic-anabolic steroid (AAS) administration on serum lipid and lipoproteins, and recovery of these variables after drug cessation, as indicators of the risk for cardiovascular disease in healthy male strength athletes.

methodsIn a non-blinded study (study 1) serum lipoproteins and lipids were assessed in 19 subjects who self administered AASs for eight or 14 weeks, and in 16 non-using volunteers. In a randomised double blind, placebo controlled design, the effects of intramuscular administration of nandrolone decanoate (200 mg/week) for eight weeks on the same variables in 16 bodybuilders were studied (study 2). Fasting serum concentrations of total cholesterol, triglycerides, HDL-cholesterol (HDL-C), HDL2-cholesterol (HDL2-C), HDL3-cholesterol (HDL3-C), apolipoprotein A1 (Apo-A1), apolipoprotein B (Apo-B), and lipoprotein (a) (Lp(a)) were determined.

resultsIn study 1 AAS administration led to decreases in serum concentrations of HDL-C (from 1.08 (0.30) to 0.43 (0.22) mmol/l), HDL2-C (from 0.21 (0.18) to 0.05 (0.03) mmol/l), HDL3-C (from 0.87 (0.24) to 0.40 (0.20) mmol/l, and Apo-A1 (from 1.41 (0.27) to 0.71 (0.34) g/l), whereas Apo-B increased from 0.96 (0.13) to 1.32 (0.28) g/l. Serum Lp(a) declined from 189 (315) to 32 (63) U/l. Total cholesterol and triglycerides did not change significantly. Alterations after eight and 14 weeks of AAS administration were comparable. No changes occurred in the controls. Six weeks after AAS cessation, serum HDL-C, HDL2-C, Apo-A1, Apo-B, and Lp(a) had still not returned to baseline concentrations. Administration of AAS for 14 weeks was associated with slower recovery to pretreatment concentrations than administration for eight weeks. In study 2, nandrolone decanoate did not influence serum triglycerides, total cholesterol, HDL-C, HDL2-C, HDL3-C, Apo-A1, and Apo-B concentrations after four and eight weeks of intervention, nor six weeks after withdrawal. However, Lp(a) concentrations decreased significantly from 103 (68) to 65 (44) U/l in the nandrolone decanoate group, and in the placebo group a smaller reduction from 245 (245) to 201 (194) U/l was observed. Six weeks after the intervention period, Lp(a) concentrations had returned to baseline values in both groups.

conclusionsSelf administration of several AASs simultaneously for eight or 14 weeks produces comparable profound unfavourable effects on lipids and lipoproteins, leading to an increased atherogenic lipid profile, despite a beneficial effect on Lp(a) concentration. The changes persist after AAS withdrawal, and normalisation depends on the duration of the drug abuse. Eight weeks of administration of nandrolone decanoate does not affect lipid and lipoprotein concentrations, although it may selectively reduce Lp(a) concentrations. The effect of this on atherogenesis remains to be established.

Indexed as

AdultAnabolic AgentsAndrogensApolipoprotein A-IApolipoproteinsApolipoproteins BCardiovascular DiseasesCholesterolCholesterol, HDLDouble-Blind MethodExerciseHumansInjections, IntramuscularLipoprotein(a)MaleNandroloneAnabolic AgentsAndrogensApolipoprotein A-IApolipoproteinsApolipoproteins BCholesterolCholesterol, HDLLipoprotein(a)NandroloneNandrolone DecanoateTriglycerides

Identifiers

PMID15155420
PMCPMC1724824
OpenAlexW2111748296

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.